Leerink Partnrs Has Negative Outlook for Zoetis Q3 Earnings

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for shares of Zoetis in a research note issued to investors on Monday, October 13th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $1.64 for the quarter, down from their prior estimate of $1.68. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.44 EPS.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $196.71.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $143.45 on Tuesday. The company has a market cap of $63.58 billion, a P/E ratio of 24.69, a PEG ratio of 2.28 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis has a one year low of $139.34 and a one year high of $196.55. The business’s 50-day simple moving average is $148.98 and its 200 day simple moving average is $154.11.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is 34.42%.

Institutional Investors Weigh In On Zoetis

A number of institutional investors have recently made changes to their positions in the company. Able Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $319,000. OLD National Bancorp IN increased its holdings in shares of Zoetis by 6.8% in the 3rd quarter. OLD National Bancorp IN now owns 35,972 shares of the company’s stock valued at $5,263,000 after acquiring an additional 2,301 shares during the last quarter. Trust Co. of Vermont boosted its position in Zoetis by 98.0% during the 3rd quarter. Trust Co. of Vermont now owns 2,735 shares of the company’s stock valued at $400,000 after purchasing an additional 1,354 shares during the period. Farther Finance Advisors LLC boosted its position in Zoetis by 15.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 13,785 shares of the company’s stock valued at $2,017,000 after purchasing an additional 1,890 shares during the period. Finally, Parcion Private Wealth LLC acquired a new position in Zoetis during the 3rd quarter valued at approximately $220,000. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.